SL 910893
Latest Information Update: 04 Nov 1998
At a glance
- Originator Sanofi-Synthelabo
- Class
- Mechanism of Action Alpha 1 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Benign prostatic hyperplasia
Most Recent Events
- 04 Nov 1998 No-Development-Reported for Benign prostatic hyperplasia in European Union (Unknown route)
- 19 Aug 1996 New profile
- 19 Aug 1996 Phase-I clinical trials for Benign prostatic hyperplasia in European Union (Unknown route)